Also in gliomas, even though clinical trials of B7-CD28 superfamily inhibitors are now under active investigation, they have ended in failure so far and most patients have received little or no obvious benefit (CheckMate-143, CheckMate-498, CheckMate-548) [39–41]. The gene discussed is CD28; the disease is glioma.